Australia Radiofrequency Ablation Device Market Product, Application, End User, States and Forecast 2026-2034

Australia Radiofrequency Ablation Device Market is projected to grow from US$ 91.63 Million in 2025 to US$ 191.74 Million by 2034, registering a CAGR of 8.55% during 2026-2034. Market growth is driven by the increasing prevalence of cardiovascular diseases, chronic pain, cancer, and minimally invasive surgical procedures. Rising healthcare expenditure, expanding adoption of advanced ablation technologies, an aging population, and continuous technological innovations in catheter-based and image-guided radiofrequency ablation systems are expected to further accelerate market expansion across Australia.

Australia Radiofrequency Ablation Device Market Outlooks

A radiofrequency ablation (RFA) device is a medical device that uses high-frequency alternating electrical current to generate controlled heat, destroying or modifying targeted abnormal tissue while minimizing damage to surrounding healthy structures. The heat is delivered through specialized electrodes, probes, needles, or catheters, making RFA a widely adopted minimally invasive treatment option. Radiofrequency ablation devices are commonly used in cardiology to treat cardiac arrhythmias such as atrial fibrillation and supraventricular tachycardia, in oncology to destroy tumors in the liver, lungs, kidneys, and bones, and in pain management to relieve chronic neck, back, and joint pain by interrupting pain-transmitting nerves. The technology is also utilized in gynecology, orthopedics, and vascular procedures.

In Australia, radiofrequency ablation devices have gained significant popularity due to the increasing prevalence of cardiovascular diseases, chronic musculoskeletal disorders, and cancer, along with a growing preference for minimally invasive treatments. Australian hospitals and specialized clinics are increasingly adopting advanced image-guided and catheter-based RFA systems because they offer shorter recovery times, reduced postoperative pain, fewer complications, and lower hospitalization costs compared with conventional surgery. Continuous investments in healthcare infrastructure, improved imaging technologies, expanding electrophysiology services, and rising awareness among healthcare professionals have further accelerated the adoption of radiofrequency ablation devices across Australia.

Prevalence of self-reported heart, stroke and vascular disease among people aged 18 and over, by age and sex, 2022-24

Prevalence by Age Group and Gender - Key Highlights

• Overall trend: The percentage increases substantially with age for both men and women, with the highest prevalence observed among individuals aged 75 years and above.
• Age 18-44 years:
• Men: ~0.6%
• Women: ~0.5%
• Persons (Overall): ~0.6%
• Lowest prevalence across all age groups.
• Age 45-54 years:
• Men: ~4.2%
• Women: ~4.1%
• Persons: ~4.3%
• Prevalence increases nearly sevenfold compared with the 18-44 age group.
• Age 55-64 years:
• Men: ~9.5%
• Women: ~7.0%
• Persons: ~8.0%
• Men show a higher prevalence than women.
• Age 65-74 years:
• Men: ~18.8%
• Women: ~9.8%
• Persons: ~14.0%
• Prevalence approximately doubles compared with the 55-64 age group.
• Men have nearly twice the prevalence of women.
• Age 75 years and above:
• Men: ~30.0%
• Women: ~21.5%
• Persons: ~25.5%
• Highest prevalence among all age categories.
• Nearly 1 in 3 men and 1 in 4 individuals overall are affected.
• Gender comparison:
• Men consistently exhibit higher percentages than women across all age groups.
• The gender gap becomes more pronounced after 55 years of age.

Growth Driver

Increasing Demand for Catheter-Based Ablation Procedures

Australia's Radiofrequency Ablation (RFA) Device Market is expanding due to the growing prevalence of cardiovascular diseases and cardiac rhythm disorders. Cardiovascular disease remains one of Australia’s leading health challenges, affecting approximately 1.3 million Australians, while heart disease accounts for nearly one in every four deaths nationwide. Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, affects an estimated 500,000 Australians, with prevalence increasing significantly among individuals aged over 65 years. Radiofrequency ablation has become a preferred treatment for patients with symptomatic AF and other arrhythmias because it offers higher long-term rhythm control than medication alone in many eligible patients. Australia continues to expand electrophysiology laboratories in tertiary hospitals, increasing procedural capacity. Improvements in three-dimensional cardiac mapping systems, irrigated ablation catheters, and contact-force sensing technology have enhanced procedural precision and safety. Growing physician expertise, increasing referral rates, and favorable clinical outcomes are expected to continue driving demand for advanced radiofrequency ablation devices across Australia’s cardiovascular care sector.

Growing Clinical Adoption Across Multiple Medical Specialties

The increasing adoption of minimally invasive treatment approaches is a major growth driver for Australia’s Radiofrequency Ablation Device Market. Australia records approximately 165,000 new cancer diagnoses annually, while chronic pain affects nearly one in five Australian adults, creating substantial demand for effective minimally invasive interventions. Radiofrequency ablation is widely used to treat liver, kidney, lung, and bone tumors that are unsuitable for conventional surgery, while also providing long-term pain relief for spinal disorders, osteoarthritis, and nerve-related chronic pain. Compared with open surgery, RFA procedures typically require smaller incisions, shorter hospital stays, reduced postoperative pain, and faster recovery. Hospitals and specialist pain clinics are increasingly integrating image-guided RFA systems using ultrasound and computed tomography to improve procedural accuracy. Growing patient preference for outpatient procedures, combined with expanding interventional radiology and pain management services, continues to strengthen adoption. Continuous innovation in electrode design, thermal monitoring, and navigation technologies is expected to further expand the use of radiofrequency ablation throughout Australia’s healthcare system.

Strengthening Hospital Infrastructure Supporting Advanced Ablation Technologies

Australia’s aging population and continued healthcare investment are significantly contributing to the growth of the Radiofrequency Ablation Device Market. Australia has a population exceeding 27 million, with approximately 17% of residents aged 65 years or older, and this proportion is expected to continue increasing over the coming decades. Older adults experience higher rates of atrial fibrillation, chronic musculoskeletal pain, osteoarthritis, and cancer, all of which represent major indications for radiofrequency ablation procedures. Australia also spends approximately 10% of its GDP on healthcare, supporting modernization of hospitals, expansion of specialist surgical centers, and adoption of advanced medical technologies. Public and private healthcare providers continue investing in electrophysiology laboratories, interventional oncology units, and pain management clinics equipped with modern ablation platforms. Enhanced diagnostic imaging, robotic navigation systems, and integrated catheter technologies have improved treatment outcomes and physician confidence. These demographic and infrastructure trends are expected to sustain long-term demand for radiofrequency ablation devices across multiple medical specialties throughout Australia.

Radiofrequency Ablation (RFA) Device Launches in Australia

• Medtronic - Affera™ Mapping and Ablation System (2025) - Commercial launch in Australia of the next-generation integrated cardiac mapping and radiofrequency ablation platform for treating complex cardiac arrhythmias.
• Johnson & Johnson MedTech (Biosense Webster) - VARIPULSE™ Platform (2025) - Australian introduction of the advanced cardiac ablation platform supporting electrophysiology procedures, complementing RF-based arrhythmia treatment workflows.
• Boston Scientific - FARAWAVE™ Navigation Software Update (2025) - Australian rollout of enhanced mapping and navigation capabilities to improve workflow efficiency in cardiac ablation procedures.
• Abbott - TactiFlex™ Ablation Catheter, Sensor Enabled™ (2024) - Australian launch of a contact-force sensing irrigated radiofrequency ablation catheter designed for atrial fibrillation and other cardiac arrhythmias.
• Biosense Webster - THERMOCOOL SMARTTOUCH™ SF Catheter Software Upgrade (2024) - Introduction of enhanced visualization and mapping features for radiofrequency catheter ablation procedures in Australia.
• Medtronic - DiamondTemp™ RF Ablation System Expansion (2024) - Expanded availability across Australian electrophysiology centers featuring temperature-controlled radiofrequency energy delivery for improved procedural precision.
• AngioDynamics - Solero® Microwave/RF Ablation Platform Update (2024) - Australian expansion of image-guided tumor ablation solutions for interventional oncology applications.
• Stryker - MultiGen 2 Radiofrequency Generator (2023) - Australian launch of an upgraded RF generator for chronic pain management and spinal nerve ablation procedures in hospitals and pain clinics.
• Avanos Medical - COOLIEF™ Cooled Radiofrequency System Expansion (2024)* - Expanded availability in Australia for minimally invasive treatment of osteoarthritis-related knee, hip, and sacroiliac joint pain.
• Teleflex - RFA Needle Electrode Portfolio Expansion (2025) - Australian launch of advanced radiofrequency ablation needle systems for image-guided liver, kidney, lung, and soft tissue tumor ablation procedures.

Challenge

Economic and Geographic Barriers to Advanced Treatment

A major challenge facing the Australia Radiofrequency Ablation Device Market is the high cost of advanced ablation procedures and unequal access to specialist care across the country. Radiofrequency ablation requires sophisticated generators, disposable catheters or probes, advanced imaging systems, and highly trained electrophysiologists or interventional specialists, making treatment relatively expensive. Although Australia’s public healthcare system provides broad access to many procedures, waiting times for elective interventions may delay treatment in some regions. Patients living in rural and remote communities often face limited access to tertiary hospitals offering cardiac electrophysiology, interventional oncology, or specialized pain management services. Australia has one of the world’s largest geographic territories with a relatively dispersed population, creating logistical challenges for specialist healthcare delivery. Travel requirements, workforce shortages, and limited procedural capacity outside metropolitan centers may reduce timely access to radiofrequency ablation. Expanding regional specialist services, telehealth support, and investment in rural healthcare infrastructure will be important to improve equitable access across Australia.

Emergence of New Energy-Based Treatment Modalities

Australia Radiofrequency Ablation Device Market is also challenged by increasing adoption of alternative ablation technologies that compete in several clinical applications. Cryoablation, microwave ablation, laser ablation, high-intensity focused ultrasound (HIFU), and pulsed field ablation (PFA) are gaining acceptance because they offer potential advantages in selected patient populations. In cardiac electrophysiology, pulsed field ablation has attracted significant attention due to its tissue-selective mechanism and potential to reduce collateral damage during atrial fibrillation procedures. Similarly, microwave ablation is increasingly used for larger tumors because it can produce higher temperatures and larger ablation zones than conventional radiofrequency systems. Hospitals continually evaluate new technologies based on procedural efficiency, clinical outcomes, physician preference, and long-term cost-effectiveness. Manufacturers of radiofrequency ablation devices must therefore invest continuously in product innovation, catheter improvements, software integration, and imaging compatibility to remain competitive. Maintaining strong clinical evidence demonstrating safety, efficacy, and economic value will be essential for sustaining market growth amid rapidly evolving minimally invasive treatment technologies.

Hospital Investment in Advanced Ablation Systems Driving Australia Market Growth

Australia Radiofrequency Ablation (RFA) Capital Equipment Market is expanding steadily as hospitals and specialty healthcare providers invest in advanced electrophysiology and interventional radiology infrastructure. Capital equipment includes radiofrequency generators, ablation consoles, mapping systems, cooling units, and image-guided navigation platforms used in cardiac, oncology, pain management, and orthopedic procedures. Australia spends approximately 10% of its GDP on healthcare, supporting modernization of tertiary hospitals and surgical facilities. Increasing demand for minimally invasive procedures has encouraged healthcare providers to replace conventional systems with high-performance RFA platforms featuring contact-force sensing, real-time temperature monitoring, and integrated imaging compatibility. Large public hospitals and private healthcare groups continue expanding electrophysiology laboratories and interventional suites to accommodate rising procedural volumes. Technological innovations improving procedural precision, treatment safety, and workflow efficiency are encouraging capital investment despite relatively high acquisition costs. Growing demand for image-guided interventions and increasing adoption of digital operating rooms are expected to sustain long-term growth in Australia’s radiofrequency ablation capital equipment market.

Increasing Cancer Burden Supporting Image-Guided Tumor Ablation in Australia

Australia Oncology Radiofrequency Ablation Device Market is witnessing robust growth due to increasing cancer incidence and greater adoption of minimally invasive tumor treatments. Australia reports approximately 165,000 new cancer cases annually, making cancer one of the country’s leading causes of illness and mortality. Radiofrequency ablation is widely used for treating liver, kidney, lung, and bone tumors, particularly among patients who are not suitable candidates for surgical resection. Image-guided procedures performed using ultrasound or computed tomography enable accurate placement of ablation probes while minimizing damage to surrounding healthy tissue. Compared with conventional surgery, radiofrequency ablation offers shorter hospital stays, faster recovery, and lower postoperative complication rates. Australian cancer centers are increasingly integrating interventional oncology into multidisciplinary treatment pathways alongside surgery, chemotherapy, and radiation therapy. Continuous improvements in electrode technology, thermal monitoring, and navigation systems have expanded treatment capabilities. Rising physician awareness and increasing patient preference for minimally invasive cancer care are expected to drive continued growth in Australia’s oncology radiofrequency ablation device market.

Growing Electrophysiology Procedures Accelerating Device Adoption in Australia

Australia Cardiology Radiofrequency Ablation Device Market represents one of the largest application segments due to increasing prevalence of cardiac arrhythmias and expanding electrophysiology services. Approximately 1.3 million Australians live with cardiovascular disease, while an estimated 500,000 people are affected by atrial fibrillation, creating sustained demand for catheter ablation procedures. Radiofrequency ablation has become a standard treatment for atrial fibrillation, atrial flutter, supraventricular tachycardia, and selected ventricular arrhythmias. Australian hospitals continue investing in advanced electrophysiology laboratories equipped with three-dimensional cardiac mapping systems, irrigated catheters, and contact-force sensing technologies that improve procedural precision and clinical outcomes. Increasing referral rates from cardiologists, greater physician experience, and growing patient awareness have contributed to rising procedural volumes nationwide. The expansion of minimally invasive cardiac interventions and continuous technological innovation in catheter design and navigation systems are expected to strengthen demand. As Australia’s aging population continues to increase, the cardiology radiofrequency ablation device market is projected to experience sustained long-term growth.

Hospitals Remaining the Largest End-User Segment in Australia

Australia Radiofrequency Ablation Device Hospital Market accounts for the largest share of demand because hospitals perform the majority of complex electrophysiology, oncology, and pain management procedures requiring advanced ablation technology. Australia has more than 1,300 public and private hospitals, many equipped with specialized cardiac catheterization laboratories, oncology departments, and interventional radiology units. Hospitals possess the multidisciplinary expertise, imaging infrastructure, anesthesia support, and postoperative care necessary for safe radiofrequency ablation procedures. Increasing numbers of minimally invasive surgeries, growing cardiovascular disease burden, and rising cancer incidence continue driving hospital utilization of RFA systems. Major tertiary hospitals are expanding electrophysiology programs while investing in advanced imaging technologies, robotic navigation, and digital operating rooms. Strong collaboration among cardiologists, oncologists, radiologists, anesthesiologists, and surgeons further supports procedural growth. Ongoing healthcare infrastructure investment and adoption of next-generation ablation platforms are expected to maintain hospitals as the dominant end-user segment in Australia’s radiofrequency ablation device market.

Australia Expansion of Ambulatory Surgical Care Supporting Market Growth

Australia Radiofrequency Ablation Device Surgical Centers Market is growing steadily as more minimally invasive procedures shift from hospitals to ambulatory surgical centers and day surgery facilities. Australia has more than 600 licensed day hospitals and day procedure centers, providing efficient outpatient treatment for selected cardiac, pain management, orthopedic, and vascular procedures. Advances in catheter technology, portable radiofrequency generators, and improved anesthesia techniques have enabled many RFA procedures to be performed safely without overnight hospitalization. Surgical centers offer reduced waiting times, lower treatment costs, and faster patient discharge compared with traditional inpatient care. Growing patient preference for minimally invasive outpatient procedures has encouraged healthcare providers to expand ambulatory service capacity. Digital imaging systems, advanced monitoring equipment, and experienced multidisciplinary teams continue improving procedural efficiency and clinical outcomes. As healthcare systems increasingly emphasize cost-effective care delivery and shorter hospital stays, ambulatory surgical centers are expected to become an increasingly important end-user segment within Australia’s radiofrequency ablation device market.

Leading Healthcare Infrastructure and High Procedure Volumes Driving Victoria Market Growth

Victoria Radiofrequency Ablation (RFA) Device Market is one of Australia’s most developed regional markets due to the state’s advanced healthcare infrastructure, strong medical research ecosystem, and high adoption of minimally invasive procedures. Victoria has a population of approximately 7 million, representing nearly 26% of Australia’s population, and Melbourne is home to several of the country’s leading tertiary hospitals and cardiovascular centers. Increasing prevalence of atrial fibrillation, chronic pain disorders, liver cancer, and musculoskeletal diseases has expanded demand for radiofrequency ablation procedures. Major hospitals continue investing in electrophysiology laboratories, image-guided interventional radiology suites, and advanced oncology treatment facilities equipped with next-generation RFA systems. Strong collaboration between universities, biotechnology companies, and healthcare providers supports rapid adoption of innovative ablation technologies. Expansion of private hospitals and ambulatory surgical centers has further increased patient access to minimally invasive procedures. Growing healthcare expenditure, improved physician expertise, and continuous investment in digital operating rooms are expected to sustain long-term growth of the Victoria Radiofrequency Ablation Device Market.

Expanding Specialist Services Improving Access Across a Large Geographic Western Australia Region

Radiofrequency Ablation Device Market is growing steadily as healthcare providers strengthen specialist services to meet increasing demand for minimally invasive treatments. Western Australia has a population of approximately 3 million, distributed across one of the world’s largest state jurisdictions, creating unique healthcare delivery challenges. Perth serves as the primary hub for advanced electrophysiology, oncology, and interventional radiology services, while regional hospitals continue expanding referral networks for complex procedures. Rising prevalence of cardiovascular disease, chronic musculoskeletal pain, and cancer has increased utilization of radiofrequency ablation technologies. Public investment in healthcare infrastructure and telehealth services has improved access to specialist consultations for patients living in remote communities. Hospitals continue upgrading catheter laboratories, imaging systems, and ablation equipment to improve treatment outcomes and procedural efficiency. Increasing physician training, expansion of multidisciplinary care teams, and growing patient awareness of minimally invasive therapies are expected to support continued market growth throughout Western Australia despite geographic challenges.

Growing Demand Supported by an Aging Population and Modern Healthcare Services in Tasmania

Tasmania Radiofrequency Ablation Device Market is experiencing gradual growth due to increasing demand for minimally invasive treatment among the state’s aging population. Tasmania has a population of approximately 580,000, with one of Australia’s oldest demographic profiles, as more than 20% of residents are aged 65 years or older. The higher prevalence of cardiovascular disease, chronic pain, osteoarthritis, and cancer among older adults has increased the need for radiofrequency ablation procedures. Major public hospitals are expanding access to interventional cardiology, pain management, and oncology services while collaborating with mainland specialist centers for highly complex cases. Improvements in diagnostic imaging, catheter technologies, and outpatient surgical services have enhanced procedural safety and patient outcomes. Telemedicine initiatives and stronger referral pathways have improved specialist access for patients living in rural and regional communities. Continued investment in healthcare infrastructure, workforce development, and minimally invasive treatment capabilities is expected to support steady expansion of the Tasmania Radiofrequency Ablation Device Market over the coming years.

Largest Healthcare Market Supporting Advanced Ablation Technologies in New South Wales

New South Wales Radiofrequency Ablation Device Market represents one of Australia’s largest regional markets due to its extensive healthcare infrastructure and large patient population. New South Wales has a population exceeding 8.5 million, making it Australia’s most populous state. Sydney hosts numerous internationally recognized tertiary hospitals, cardiovascular institutes, comprehensive cancer centers, and specialized pain management clinics that perform high volumes of radiofrequency ablation procedures. Increasing incidence of atrial fibrillation, chronic pain conditions, liver tumors, and musculoskeletal disorders continues driving demand for advanced ablation devices. Public and private hospitals are investing in modern electrophysiology laboratories, robotic-assisted interventions, high-resolution imaging systems, and next-generation radiofrequency generators to improve treatment precision and clinical outcomes. Strong participation in clinical research, physician training programs, and adoption of minimally invasive technologies further strengthen market development. Growing healthcare expenditure, an aging population, and increasing patient preference for minimally invasive procedures are expected to sustain robust long-term growth in the New South Wales Radiofrequency Ablation Device Market.

Market Segmentations

Product

• Capital Equipment
• Disposable Equipment
• Reusable Equipment

Application

• Oncology
• Cardiology
• Cosmetic Surgery
• Gynecology
• Others

End User

• Hospitals
• Ambulatory Surgical Centers
• Others

States

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Australian Capital Territory
• Tasmania
• Northern Territory

All the Key players have been covered

• Overview
• Key Persons
• Recent Development
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• Boston Scientific Corporation, Inc.
• Abbott Laboratories
• AtriCure, Inc.
• Medtronic plc
• Stryker
• Smith & Nephew plc
• Conmed Corporation
• Hologic, Inc.